Skip to content

Study · Not a test of the peptide alone · 2014

2 results

Rationally designed, nontoxic, nonamyloidogenic analogues of human islet amyloid polypeptide with improved solubility.

Wang H, Abedini A, Ruzsicska B, Raleigh DP

Biochemistry11 Sept 2014Cited by 35 (Europe PMC)

PMID25140605 (opens in a new tab)PMCIDPMC4172205 (opens in a new tab)DOI10.1021/bi500592p (opens in a new tab)PepBankPUB-25140605
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Pramlintide (Symlin).

  1. 01LabNot a test of Pramlintide (Symlin) aloneIn vitro (cell-free)Activity measurement

    In laboratory tests at neutral pH, pramlintide was less soluble than the H18R triple and quadruple amylin mutants.

    In plain wordsIn lab tests at neutral pH, pramlintide was less soluble than the tested H18R triple and quadruple mutants.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseSolubility versus H18R triple and quadruple mutants
    Study

    n: not reported in source

    Comparator
    H18R/G24P/I26P and H18R/A25P/S28P/S29P mutants
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    An H18R/G24P/I26P triple mutant and an H18R/A25P/S28P/S29P quadruple mutant are significantly more soluble at neutral pH than hIAPP or PM.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

  2. 02LabNot a test of Pramlintide (Symlin) aloneIn vitro (cell-free)Activity measurement

    In laboratory tests, pramlintide was less soluble than the S20R triple and H18R double amylin mutants.

    In plain wordsIn lab tests, pramlintide was less soluble than the tested S20R triple and H18R double mutants.

    Peptide
    Pramlintide (Symlin)
    Outcome
    DecreaseSolubility versus S20R triple and H18R double mutants
    Study

    n: not reported in source

    Comparator
    S20R/G24P/I26P and H18R/I26P mutants
    Outcome group
    Receptor activity and mechanism · Pharmacology

    Source sentences

    Summary
    To illustrate this point, we show that an S20R/G24P/I26P triple mutant and an H18R/I26P double mutant are nonamyloidogenic and significantly more soluble than human IAPP or PM.

    In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.